Preladenant, an adenosine A2A receptor antagonist, was observed to be improving the on time associated with L-DOPA therapy, without changing the dyskinesia state in individuals with moderate to severe PD in a double-blinded, placebo-controlled RCT (Hauser et al., 2015). Here, ADORA2A is linked to Parkinson disease.